Aptinyx slides after pricing equity offering

Aptinyx

22/10/2020 11:39

** Aptinyx Inc  APTX.O  shares down ~13% premarket after
biopharma prices follow-on
    ** Co sells 14 mln shares at $3, raises $42 mln to advance
development of its drug candidates to treat brain and nervous
system disorders  urn:newsml:reuters.com:*:nBw2R8R17a
    ** Offering size increased from 12 mln shares, prices at
~23% discount to stock's Weds close
    ** SVB Leerink, Piper Sandler, Cantor and Wedbush jt
bookrunners for offering
    ** On Tues, APTX surged >17% to $4.30 after co late Mon said
treatment for post-traumatic stress disorder (PTSD), NYX-783,
showed statistically significant and clinically meaningful
efficacy results in mid-stage study  urn:newsml:reuters.com:*:nBwc2lh2Pa
    ** APTX has ~47 mln shares outstanding and ~39 mln shares of
free float, per Refinitiv data
    ** Stock up 14% YTD

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com))